Your browser is no longer supported. Please, upgrade your browser.
Settings
ARRY Array BioPharma Inc. daily Stock Chart
ARRY [NASD]
Array BioPharma Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own0.30% Shs Outstand207.84M Perf Week8.03%
Market Cap4.03B Forward P/E- EPS next Y-0.61 Insider Trans-44.56% Shs Float207.84M Perf Month22.91%
Income-124.50M PEG- EPS next Q-0.26 Inst Own96.30% Short Float7.39% Perf Quarter17.39%
Sales172.10M P/S23.39 EPS this Y-10.20% Inst Trans-1.80% Short Ratio5.87 Perf Half Y77.22%
Book/sh1.27 P/B15.25 EPS next Y17.60% ROA-28.60% Target Price21.38 Perf Year121.12%
Cash/sh2.11 P/C9.18 EPS next 5Y10.00% ROE-66.80% 52W Range7.15 - 20.21 Perf YTD51.33%
Dividend- P/FCF- EPS past 5Y-16.50% ROI-71.10% 52W High-4.16% Beta1.68
Dividend %- Quick Ratio5.70 Sales past 5Y12.10% Gross Margin69.00% 52W Low170.91% ATR0.87
Employees209 Current Ratio5.70 Sales Q/Q99.40% Oper. Margin-67.30% RSI (14)67.88 Volatility6.71% 5.16%
OptionableYes Debt/Eq0.40 EPS Q/Q47.70% Profit Margin-72.30% Rel Volume1.02 Prev Close19.55
ShortableYes LT Debt/Eq0.36 EarningsMay 09 BMO Payout- Avg Volume2.61M Price19.37
Recom1.60 SMA2010.61% SMA5022.75% SMA20038.16% Volume2,660,755 Change-0.92%
Feb-07-18Reiterated Stifel Buy $20 → $23
Jan-22-18Upgrade Leerink Partners Mkt Perform → Outperform
Jan-22-18Reiterated Stifel Buy $15 → $20
Sep-11-17Reiterated Stifel Buy $13 → $15
May-03-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Reiterated Stifel Buy $8 → $13
Feb-03-17Downgrade JP Morgan Overweight → Neutral
Jan-30-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-26-16Reiterated Piper Jaffray Overweight $7 → $10
Sep-26-16Reiterated Leerink Partners Outperform $6 → $9
Jan-26-15Reiterated Stifel Buy $6 → $9
Aug-09-13Reiterated Stifel Buy $7 → $8
Jul-23-10Upgrade UBS Neutral → Buy $4.25
Apr-22-10Downgrade UBS Buy → Neutral
Nov-05-09Upgrade UBS Neutral → Buy
Sep-08-09Downgrade UBS Buy → Neutral
Sep-04-09Downgrade Robert W. Baird Outperform → Neutral $10 → $3
Sep-04-09Downgrade Leerink Swann Outperform → Mkt Perform $6 → $2
Sep-04-09Downgrade Boenning & Scattergood Outperform → Neutral
Jun-17-09Initiated Boenning & Scattergood Outperform $6
Jun-21-18 08:49AM  Array BioPharma (ARRY) Looks Good: Stock Adds 5.2% in Session Zacks
Jun-20-18 03:55PM  Harry Boxer: Marijuana companies Aurora Cannabis and Canopy Growth are breaking out MarketWatch +5.21%
08:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Array BioPharma ACCESSWIRE
Jun-18-18 08:00AM  Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer PR Newswire
Jun-17-18 04:16PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-05-18 09:37AM  Are New Drug Approvals Right Around the Corner for Trevena (TRVN) and Array Biopharma (ARRY)? SmarterAnalyst +5.09%
Jun-04-18 10:10AM  What does Array BioPharma Incs (NASDAQ:ARRY) Balance Sheet Tell Us About Its Future? Simply Wall St.
08:00AM  Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma PR Newswire
Jun-01-18 03:56PM  Key FDA Events in June Investors Need to Watch Out For Zacks
May-31-18 09:32AM  George Soros Bought This Clinical-Stage Biotech Stock. Should You? Motley Fool
06:31AM  3 Biotechs With Huge FDA Decisions in June Motley Fool
May-30-18 04:05PM  Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-18-18 04:12AM  Edited Transcript of ARRY earnings conference call or presentation 9-May-18 1:00pm GMT Thomson Reuters StreetEvents
May-16-18 05:17PM  Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting PR Newswire
07:05AM  Free Stock Performance Review on Array BioPharma and Three More Biotech Industry ACCESSWIRE
May-15-18 07:00AM  Wired News Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China ACCESSWIRE
May-11-18 08:39AM  Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher Zacks
03:40AM  Will Array Biopharma Break Its Downtrend? Investopedia
May-09-18 04:05PM  Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference PR Newswire
11:39AM  Array BioPharma Inc (NASDAQ:ARRY): Should The Recent Earnings Drop Worry You? Simply Wall St.
08:14AM  Array BioPharma: Fiscal 3Q Earnings Snapshot Associated Press
08:00AM  Array BioPharma Reports Financial Results For The Third Quarter of Fiscal 2018 PR Newswire
May-06-18 06:19PM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
May-03-18 10:17AM  What's in the Cards for Geron (GERN) This Earnings Season? Zacks
10:13AM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
Apr-30-18 04:05PM  Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018 PR Newswire
Apr-13-18 08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical ACCESSWIRE
Apr-03-18 08:39AM  Is There An Opportunity With Array BioPharma Incs (NASDAQ:ARRY) 32% Undervaluation? Simply Wall St.
Mar-26-18 08:20AM  Todays Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc. ACCESSWIRE
Mar-22-18 09:00AM  Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology PR Newswire
Mar-05-18 04:01PM  Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference PR Newswire
Feb-22-18 06:00AM  A Six-Pack of Biotech Bets Investopedia
Feb-21-18 08:10AM  New Research Coverage Highlights Timken Steel, National Health Investors, Donaldson, Array BioPharma, Impax Laboratories, and Baxter International Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-16-18 08:36AM  Options Traders Expect Huge Moves in Array BioPharma (ARRY) Stock Zacks
Feb-14-18 09:07AM  Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget Zacks
Feb-10-18 10:33AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-08-18 08:10AM  Todays Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle Genetics ACCESSWIRE
07:40AM  Wired News Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases ACCESSWIRE
Feb-07-18 04:05PM  Array BioPharma To Present At The LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire +7.80%
02:55PM  Edited Transcript of ARRY earnings conference call or presentation 6-Feb-18 2:00pm GMT Thomson Reuters StreetEvents
11:23AM  Harry Boxers three stocks breaking out on earnings news MarketWatch
10:23AM  Array's Melanoma Combo Shows Positive Overall Survival Data Zacks
Feb-06-18 03:55PM  Here's Why Array BioPharma Inc. Is Rising Today Motley Fool +15.54%
12:39PM  Does Array BioPharma Incs (NASDAQ:ARRY) Debt Level Pose A Problem? Simply Wall St.
10:54AM  Array melanoma drugs show significant survival vs Roche drug in study Reuters
08:17AM  Array BioPharma reports 2Q loss Associated Press
08:05AM  Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018 PR Newswire
08:00AM  Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial PR Newswire
08:00AM  Array melanoma drugs show significant survival vs Roche drug in study Reuters
07:15AM  Array BioPharma Inc. to Host Earnings Call ACCESSWIRE
Feb-05-18 08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and TG Therapeutics ACCESSWIRE -5.31%
Feb-01-18 07:45PM  PRESS DIGEST- British Business - Feb 2 Reuters
05:58PM  AstraZeneca is sued by Array BioPharma over cancer drug royalties Reuters
Jan-30-18 09:00AM  Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018 PR Newswire
Jan-26-18 07:34AM  Taking Stock of Radius Healths Financial Performance Market Realist
Jan-25-18 03:15PM  Taking Stock of Radius Healths Licensing Agreements Market Realist
12:13PM  Analysts Ratings for Radius Health and Its Peers in January Market Realist
Jan-23-18 01:52PM  Mylan CEO: I'm excited about our pipeline Yahoo Finance Video
08:10AM  Todays Research Reports on Stocks to Watch: Array BioPharma and Sorrento Therapeutics ACCESSWIRE
Jan-22-18 11:56AM  Why Array BioPharma Inc. Is Soaring Motley Fool +18.42%
11:05AM  DEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE
10:38AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline: January 22, 2018 ACCESSWIRE
Jan-20-18 10:05AM  Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial PR Newswire
Jan-18-18 02:00PM  ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018 ACCESSWIRE
10:30AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018 ACCESSWIRE
Jan-17-18 02:44PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE
02:32PM  FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact The Firm GlobeNewswire
01:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
Jan-16-18 11:36AM  The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY) ACCESSWIRE -5.40%
10:37AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline: January 22, 2018 ACCESSWIRE
08:00AM  Array BioPharma to Present Updated Phase 3 BEACON CRC Safety Lead-In Results of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the 2018 Gastrointestinal Cancers Symposium PR Newswire
Jan-14-18 01:00PM  ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018 ACCESSWIRE
Jan-13-18 07:31AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
Jan-12-18 04:23PM  ARRY LOSS ALERT: Rosen Law Firm Reminds Array Biopharma Inc. Investors of Important January 22 Deadline in Class Action ARRY GlobeNewswire
08:04AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
08:00AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE
Jan-11-18 05:18PM  ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm ACCESSWIRE
05:00PM  The Klein Law Firm Reminds Shareholders of a Class Action Commenced on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY) ACCESSWIRE
Jan-10-18 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
08:10AM  Todays Research Reports on Trending Tickers: Array BioPharma and Nektar Therapeutics ACCESSWIRE
03:00AM  Stocks Showing Market Leadership: Array Biopharma Earns 91 RS Rating Investor's Business Daily
Jan-09-18 11:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE +7.63%
10:37AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018 ACCESSWIRE
08:03AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Jan-08-18 12:45PM  ARRY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018 ACCESSWIRE
Jan-06-18 12:46PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
Jan-05-18 11:50AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE
10:36AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Array Biopharma, Inc. (ARRY) & Lead Plaintiff Deadline - January 22, 2018 ACCESSWIRE
Jan-03-18 04:00PM  The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY) GlobeNewswire
12:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
Jan-02-18 02:30PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 - ARRY ACCESSWIRE +5.86%
10:00AM  Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference PR Newswire
08:04AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Dec-30-17 08:15AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline ARRY Business Wire
Dec-29-17 02:09PM  ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018 GlobeNewswire
Dec-28-17 03:43PM  Lifshitz & Miller LLP Announces Investigation of Alteryx, Inc., Array BioPharma Inc., Bruker Corporation, Eagle Bancorp, Inc., Omega Healthcare Investors, Inc., Otsuka Holdings Co., Ltd., Tivity Health, Inc. and Triangle Capital Corporation PR Newswire
02:11PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 ARRY GlobeNewswire
12:23PM  Array BioPharma spins off cardiovascular myopathy drug research into new subsidiary American City Business Journals
Dec-27-17 07:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline - ARRY ACCESSWIRE
01:14PM  The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY) ACCESSWIRE
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAN LUNSEN GIL JDirectorJun 20Option Exercise4.8621,500104,52040,797Jun 21 04:20 PM
VAN LUNSEN GIL JDirectorJun 20Sale19.0821,500410,22019,297Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 19Option Exercise3.6577,576283,152287,662Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 19Sale18.7677,5761,455,326210,086Jun 21 04:20 PM
Sandor VictorChief Medical OfficerJun 13Option Exercise3.6522,42481,848232,510Jun 15 04:25 PM
Sandor VictorChief Medical OfficerJun 13Sale18.7522,424420,450210,086Jun 15 04:25 PM
VAN LUNSEN GIL JDirectorMay 16Option Exercise4.1521,50089,33040,797May 17 04:01 PM
VAN LUNSEN GIL JDirectorMay 16Sale15.3621,500330,25919,297May 17 04:01 PM
VAN LUNSEN GIL JDirectorApr 18Option Exercise3.7821,50081,22540,797Apr 18 04:38 PM
VAN LUNSEN GIL JDirectorApr 18Sale15.1921,500326,58519,297Apr 18 04:38 PM
Sandor VictorChief Medical OfficerApr 03Sale15.358,689133,376210,086Apr 03 06:49 PM
Sandor VictorChief Medical OfficerApr 01Option Exercise0.007,8120225,711Apr 03 06:49 PM
Robbins Andrew RCOOApr 01Option Exercise0.009,8440168,142Apr 03 06:48 PM
Squarer RonCEOApr 01Option Exercise0.0018,9060228,180Apr 03 06:48 PM
Saccomano Nicholas ACSOApr 01Option Exercise0.006,875061,396Apr 03 06:48 PM
VAN LUNSEN GIL JDirectorMar 21Option Exercise3.4621,50074,48540,797Mar 21 05:11 PM
VAN LUNSEN GIL JDirectorMar 21Sale16.7621,500360,34019,297Mar 21 05:11 PM
Sandor VictorChief Medical OfficerMar 09Option Exercise3.65182,191664,997373,915Mar 09 05:42 PM
Sandor VictorChief Medical OfficerMar 09Sale17.71156,0162,763,714217,899Mar 09 05:42 PM
VAN LUNSEN GIL JDirectorFeb 21Option Exercise2.8021,50060,17040,797Feb 23 04:35 PM
VAN LUNSEN GIL JDirectorFeb 21Sale17.1621,500368,94019,297Feb 23 04:35 PM
BAUM CHARLES MDirectorFeb 09Option Exercise5.5450,000277,00060,000Feb 12 05:26 PM
LEFKOFF KYLEDirectorFeb 09Option Exercise4.7450,000236,75067,720Feb 12 05:27 PM
LEFKOFF KYLEDirectorFeb 09Sale17.0150,000850,50017,720Feb 12 05:27 PM
BAUM CHARLES MDirectorFeb 09Sale16.9050,000845,00010,000Feb 12 05:26 PM
VAN LUNSEN GIL JDirectorJan 17Option Exercise1.9621,50042,09040,797Jan 17 05:00 PM
VAN LUNSEN GIL JDirectorJan 17Sale12.9421,500278,21019,297Jan 17 05:00 PM
Haddock JasonCFOJan 16Option Exercise3.7714,02552,87436,368Jan 16 04:28 PM
Haddock JasonCFOJan 16Sale13.737,500102,97528,868Jan 16 04:28 PM
Squarer RonCEODec 19Option Exercise5.18546,2332,829,457755,507Dec 19 09:05 PM
Squarer RonCEODec 19Sale10.93546,2335,970,327209,274Dec 19 09:05 PM
Robbins Andrew RCOODec 18Option Exercise4.96397,5001,973,225441,172Dec 19 09:05 PM
Squarer RonCEODec 18Option Exercise6.08354,5092,156,168482,712Dec 19 09:05 PM
Squarer RonCEODec 18Sale10.73273,4382,933,990209,274Dec 19 09:05 PM
Robbins Andrew RCOODec 18Sale10.72282,8743,032,409158,298Dec 19 09:05 PM
Haddock JasonCFODec 16Option Exercise0.004,387024,387Dec 19 09:07 PM
Sandor VictorChief Medical OfficerDec 16Option Exercise8.7911,28499,186197,034Dec 19 09:04 PM
Squarer RonCEODec 16Option Exercise0.0023,4370139,120Dec 19 09:05 PM
Saccomano Nicholas ACSODec 16Option Exercise0.005,468057,069Dec 19 09:05 PM
Robbins Andrew RCOODec 16Option Exercise0.0013,082049,766Dec 19 09:05 PM
VAN LUNSEN GIL JDirectorOct 27Option Exercise10.475,00052,35020,332Oct 27 04:36 PM
BAUM CHARLES MDirectorOct 27Option Exercise10.475,00052,35010,000Oct 27 04:32 PM
LEFKOFF KYLEDirectorOct 27Option Exercise10.475,00052,35017,720Oct 27 04:32 PM
Orwin John ADirectorOct 27Option Exercise10.475,00052,35010,000Oct 27 04:32 PM
Fyfe Gwen A.DirectorOct 27Option Exercise10.475,00052,35010,000Oct 27 04:28 PM
LEFKOFF KYLEDirectorSep 29Option Exercise10.5845,000476,10051,585Sep 29 06:22 PM
VAN LUNSEN GIL JDirectorSep 29Option Exercise10.5845,000476,10055,260Sep 29 06:23 PM
VAN LUNSEN GIL JDirectorSep 29Sale12.3639,928493,51015,332Sep 29 06:23 PM
LEFKOFF KYLEDirectorSep 29Sale12.3138,865478,42812,720Sep 29 06:22 PM
Haddock JasonCFOAug 14Option Exercise3.7720,00075,40020,000Aug 15 04:31 PM